BTK and rheumatoid arthritis: A new drug that has been successfully investigated in RA patients in a phase II trial is spebrutinib (CC-292), the first irreversible Bruton’s tyrosine kinase (BTK) inhibitor [156] and fenebrutinib, a highly selective non-covalent BTK inhibitor [156].